Clinical trial • Not applicable • Other
Human albumin solution for Perioperative fluid therapy in laparoscopic abdominal surgery
Not applicable trial of Human albumin solution for Perioperative fluid therapy in laparoscopic abdominal surgery.
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Perioperative fluid therapy in laparoscopic abdominal surgery
- Trial Stage
- Not applicable
- Drug Modality
- Small molecule|Peptide/protein/enzyme
Key dates
- Initial CTIS Submission Date
- 15-04-2024
- First CTIS Authorization Date
- 26-04-2024
Trial design
Comparator arms: Albumin (human albumin solution, intravenous; product max daily/total amount listed as 50 g) versus Ringer's solution/electrolytes (intravenous; product max daily/total amount listed as 3 L). Administration is intravenous during planned laparoscopic abdominal surgery; treatment described as fluid infusion.-controlled Not applicable trial across 2 sites in Sweden.
- Comparator
- Comparator arms: Albumin (human albumin solution, intravenous; product max daily/total amount listed as 50 g) versus Ringer's solution/electrolytes (intravenous; product max daily/total amount listed as 3 L). Administration is intravenous during planned laparoscopic abdominal surgery; treatment described as fluid infusion.
- Target Sample Size
- 60
- Trial Duration For Participant
- 1
Eligibility
Recruits 60 No vulnerable population selected. Written informed consent from the participant is required ("Forskningspersonen har gett sitt skriftliga samtycke till att delta i studien."). Individuals with mental incapacity, reading, vision or language difficulties are excluded ("Mental oförmåga, läs, syn eller språksvårigheter som medför svårighet att förstå innebörden av att delta i studien")..
- Pregnancy Exclusion
- Graviditet, amning eller planerad graviditet.
- Vulnerable Population
- No vulnerable population selected. Written informed consent from the participant is required ("Forskningspersonen har gett sitt skriftliga samtycke till att delta i studien."). Individuals with mental incapacity, reading, vision or language difficulties are excluded ("Mental oförmåga, läs, syn eller språksvårigheter som medför svårighet att förstå innebörden av att delta i studien").
Inclusion criteria
- {"criterion_text":"- Forskningspersonen har gett sitt skriftliga samtycke till att delta i studien."}
- {"criterion_text":"- För kvinnliga deltagare i fertil ålder ska adekvat preventivmedel användas, t.ex. P-piller, spiral eller P-stav eller ett negativt graviditetstest. För postmenopausala gäller ingen mens på 12 månader för att frångå kravet på effektiv preventivmedel."}
- {"criterion_text":"- Deltagare ska tillhöra ASA (American Society of Anesthesiology) klassificering I till III."}
- {"criterion_text":"- Planerad större laparoskopisk bukkirurgi, som planeras vara i 90 minuter eller mer."}
- {"criterion_text":"- 18 till 85 års ålder"}
Exclusion criteria
- {"criterion_text":"- Patienter med känd hjärtsvikt"}
- {"criterion_text":"- <18 år eller >80 år"}
- {"criterion_text":"- Känd eller misstänkt allergi mot albumin, överkänslighet mot de aktiva substanserna eller mot något hjälpämne."}
- {"criterion_text":"- Extracellulär hyperhydrering eller hypervolemi"}
- {"criterion_text":"- Uttalad njurfunktionsnedsättning."}
- {"criterion_text":"- Graviditet, amning eller planerad graviditet."}
- {"criterion_text":"- Mental oförmåga, läs, syn eller språksvårigheter som medför svårighet att förstå innebörden av att delta i studien"}
- {"criterion_text":"- Deltar eller nyligen deltagit eller i en klinisk läkemedelsprövning, de senaste 30 dagarna. Tidigare deltagande i denna studie."}
Endpoints
Primary endpoints
- {"endpoint_text":"- Hemoglobinsänkning i samband med vätskebolus, vilken bearbetas matematiskt i en kinetisk modell.","definition_or_measurement_approach":"Decrease in hemoglobin associated with a fluid bolus, analysed/processed mathematically using a kinetic model."}
Secondary endpoints
- {"endpoint_text":"- Cirkulationsfysiologiska mätningar. Förändring i P-albumin, P-Kreatinin, Vätskesammansättning och vätskebalans preoperativt och efter ett dygn.","definition_or_measurement_approach":"Circulatory physiological measurements: changes in plasma albumin (P-albumin), plasma creatinine (P-Kreatinin), fluid composition and fluid balance measured preoperatively and 24 hours postoperatively."}
Recruitment
- Planned Sample Size
- 60
- Recruitment Window Months
- 38
- Consent Approach
- Written informed consent is required from each participant ("Forskningspersonen har gett sitt skriftliga samtycke till att delta i studien."). For females of childbearing potential, effective contraception or a negative pregnancy test is required. No information provided on assent for minors (minors are excluded). No languages or translated documents specified.
Geography
- Total Number Of Sites
- 2
- Total Number Of Participants
- 60
Sweden
- Earliest CTIS Part Ii Submission Date
- 02-04-2024
- Latest Decision Or Authorization Date
- 26-04-2024
- Processing Time Days
- 24
- Number Of Sites
- 2
- Number Of Participants
- 60
Sites
- Site Name
- Vrinnevisjukhuset I Norrkoeping Region Oestergoetland
- Department Name
- Anestesi och intensivvårdskliniken, Norrköping
- Contact Person Name
- Robert Svensson
- Contact Person Email
- robert.svensson@regionostergotland.se
- Site Name
- Region Oestergoetland (Universitetssjukhuset I Linkoping)
- Department Name
- Anestesi och intensivvårdskliniken, Linköping
- Contact Person Name
- Hans Bahlmann
- Contact Person Email
- hans.bahlmann@regionostergotland.se
Sponsor
Primary sponsor
- Full Name
- Region Oestergoetland
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Sweden
Investigational products
- Investigational Product Name
- ELECTROLYTES
- Modality
- Small molecule
- Routes Of Administration
- Intravenous
- Route
- Intravenous
- Authorisation Status
- Product authorisation status code: 2; marketingAuthorisationNumber: -
- Maximum Dose
- 3 l
- Investigational Product Name
- ALBUMIN
- Active Substance
- Human albumin solution
- Modality
- Peptide/protein/enzyme
- Routes Of Administration
- Intravenous
- Route
- Intravenous
- Authorisation Status
- Product authorisation status code: 2; marketingAuthorisationNumber: -
- Maximum Dose
- 50 g
Related trials
Other published trials that may interest you.